
#Spreading +ive vibes via My #StressBusters🕺 #Screening #Investing #Educating No paid services!
Joined September 2012
- Tweets9.7K
- Following117
- Followers26.3K
- Likes12.7K
Pinned Tweet
A compilation of all my Important #Threads & #screeners !👇
Spread the word, if you find this helpful for investors!
@Vivek_Investor @Atulsingh_asan @abhymurarka @nid_rockz
👇👇👇
Watched Ramayana Part 1 3D with family yesterday. Kids loved it. I asked Ridit what he found most exciting.
His innocent reply: "Dad, Ram had 14 yrs of adventure!" 😂
We went to watch Ramayana, but he came away thinking Lord Ram had signed up for a 14yr adventure package! 🤣🏹
1
17
3,635
Navin Fluorine CMP Rs 10000 stands out on key quality screens:
✅ Low free float (~1 Cr)
✅ Operating leverage (profit growth > sales growth)
✅ 5-yr steady sales/profit growth & 3-yr positive FCF amid Capex
✅ Strong ROE/ROCE, low debt & stable holdings
Navin Fluorine loading 5 digits... 🔥
Abki baar 10,000 paar! 🚀🚀
Navin Fluorine: "Aapki Baar, ₹8,000 Paar!" 🚀
Manifesting... but with earnings support. 😉 #NavinFluorine
Sachin K Rai retweeted
Replying to @hd_hitendra
ABB India
Anantraj
Cartrade
CDSL
Fineotex Chemicals
Havells
MCX
Navin Fluorine
Netweb
Precision Wires
R Systems
Added during last 2 sessions.
R Systems Rs 280 up 13%
Still ~53% below ATH
Q3 CY26
Revenue & PAT growth 💪
EBITDA growth 👌
Margin expansion +ive
Sequential momentum +ive
Other-income dependency - Low in Q3
Finance costs-Monitor
AI business opportunity-Promising
Not a recommendation to buy or sell.
1/ 🧵 R Systems
CMP: ₹250 | Market Cap: ₹2,970 Cr
~58% below ATH.
Two consecutive quarters of strong operating growth ahead of Nov 3 results.
Q2 CY26: Revenue +30.2% | Adjusted EBITDA +51.4% YoY
Q1 CY26: Revenue +29.9% | Adjusted EBITDA +51.0% YoY
Worth a closer look. 👇
15
2,383
1 🧵 Affle 3i acquires Perion Network for $420M!
Perion brings global reach, US market access and capabilities across CTV, Retail Media and Digital Out-of-Home advertising.
Is this a transformational acquisition for Affle? Let's look at the opportunity. 👇
5/ What about the funding?
Deal value: $420M
Perion cash: $228M
Perion is debt free
Affle plans to use bank financing and available cash. Management expects combined group to be net-debt-free post acquisition & the deal to become EPS-accretive within the 1st year after closing.
1
4
455
1/ 🧵 R Systems
CMP: ₹250 | Market Cap: ₹2,970 Cr
~58% below ATH.
Two consecutive quarters of strong operating growth ahead of Nov 3 results.
Q2 CY26: Revenue +30.2% | Adjusted EBITDA +51.4% YoY
Q1 CY26: Revenue +29.9% | Adjusted EBITDA +51.0% YoY
Worth a closer look. 👇
6/ Novigo acquisition + AI ambitions
R Systems acquired Novigo Solutions for ₹400 Cr, strengthening its automation and enterprise technology capabilities.
Combining Novigo's automation expertise with R Systems' OptimaAI platform to build agentic AI solutions.
1
3
715
From Manchester Organics in 2011 → Navin Molecular in 2023.
Grams to tonnes.
From doubt to $100 mn visibility.
Navin Fluorine taught me one thing:
The best businesses don’t scream every quarter.
They just keep building plants, molecules, and moats.
Top holding since 2011.
How compounding takes place in Businesses?
A co where 2020's Topline will be their FY27's PAT.
Navin Fluorine’s CDMO business is the one the market had written off. In Q4 FY24 it did just Rs 48 crore, down 76% after molecules got deferred. In Q2 FY27, it was the company’s fastest-growing vertical, with revenue up 78% YoY to Rs 239 crore. That’s roughly 5x in ten quarters.
The story behind that jump starts fifteen years ago in a lab in England. In 2011, Navin bought 51% of UK-based Manchester Organics for £4.335 million.
The company was founded in 1996 and specialised in lab-scale, multi-step synthesis. Navin got a call option on the remaining 49%, and the promoters got a put option, exercisable after four years. Navin took the rest in October 2015.
The advantage is easiest to see if you think of CDMO as a funnel. A molecule is first made in grams for discovery, then in kilos for trials, then in tonnes if it gets approved. Manchester Organics works with innovators at that early discovery stage, and it brings deep expertise in fluorination and high-pressure chemistry. Owning it is like owning a cricket academy: you meet the players before anyone knows they’re stars.
In the same year, Navin commissioned a cGMP pilot plant at Dewas, so the molecules it met early had somewhere to scale. Dewas was then built out one plant at a time.
A multipurpose cGMP plant for CRAMS came in 2015, and the next cGMP addition started commercial production in January 2020. In 2023 the division got its own name, Navin Molecular. The real inflection came that year with a 3-year supply agreement with Fermion starting CY2025. To serve it, Navin committed Rs 288 crore to cGMP-4, a 200 KL plant built in two phases, which nearly doubles the site’s capacity to 420 m³. Phase 1 began commercial production on 31 December 2025.
The Q2 FY27 concall filled in the next chapter. Phase 2 of cGMP-4 (about Rs 125 crore) goes live by the end of Q4 FY27, and both phases are dedicated entirely to Fermion.
The $100 million FY27 target is within striking distance on order book visibility. Two pipeline molecules are moving. One has been approved in China and is on fast track for FDA approval. The other is a label expansion of darolutamide itself.
While building Phase 2, Navin built warehousing up to Phase 6 and effluent treatment up to Phase 5, so it can move to cGMP-5 quickly. Management said it will trigger Phase 5 as soon as GMP utilisation reaches 70-80%. That means three legacy plants, cGMP-4 in two phases, cGMP-5 ready to go, and room for a sixth.
On revenue, management puts the peak potential of cGMP-4’s two phases at close to 3x the capital invested, or about Rs 900-1,000 crore by FY28-29.
Disclaimer: No recommendation to buy or sell. Data from @stockscansin
15
3,081
Navin Fluorine continues to impress @sonalbhutra
Navin fluorine
Strong set! Management commentary positive.
Q2FY27-YoY
Revenue up 57% at 1190cr vs 758cr
EBITDA up 65%at 407cr vs 246cr
OPM at 34.2% vs 32.4%
PAT up 82% at 269cr vs 147cr
Stock trades at 28X FY28 EPS
14
2,805







